# A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer

> **NCT00490646** · PHASE2 · COMPLETED · sponsor: **R-Pharm** · enrollment: 50 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** ixabepilone
- **DRUG:** docetaxel
- **DRUG:** trastuzumab

## Key facts

- **NCT ID:** NCT00490646
- **Lead sponsor:** R-Pharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2011-06
- **Final completion:** 2011-11
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2016-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00490646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00490646, "A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00490646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*